Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dexcom First To CGM Reimbursement Finish Line

Executive Summary

Following a recent approval for their G5 continuous glucose monitor for use in children and adults without a finger stick, Dexcom has scored big with a new US Centers for Medicaid and Medicare Services policy that would make their CGM the first of its kind eligible for reimbursement from the agency.


Related Content

Abbott Gains Go-Ahead For First 'No-Fingerstick' CGM
Dexcom Looks To Expansion, Operational Efficiency For Rapid Growth
Number To Know…1
Dexcom Glucose Test System Approved For 2-Year-Olds
FDA Panel Overwhelmingly Votes For Dexcom CGM to Replace Finger Sticks


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts